223 related articles for article (PubMed ID: 32793461)
1. Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
Bai R; Chen N; Liang T; Li L; Lv Z; Lv X; Cui J
Front Oncol; 2020; 10():912. PubMed ID: 32793461
[TBL] [Abstract][Full Text] [Related]
2. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Zhang Z; Xie T; Zhang X; Qi C; Shen L; Peng Z
Chin J Cancer Res; 2020 Jun; 32(3):287-302. PubMed ID: 32694895
[TBL] [Abstract][Full Text] [Related]
4. A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas.
Shankaran V; Xiao H; Bertwistle D; Zhang Y; You M; Abraham P; Chau I
Adv Ther; 2021 Jan; 38(1):707-720. PubMed ID: 33244736
[TBL] [Abstract][Full Text] [Related]
5. The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review.
AlMazmomy AM; Al-Hayani MM; Alomari M; Bazi AG
Cureus; 2019 Dec; 11(12):e6295. PubMed ID: 31938588
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis.
Kim JH; Kim HS; Kim BJ; Jang HJ
Oncotarget; 2017 Nov; 8(57):97565-97570. PubMed ID: 29228632
[TBL] [Abstract][Full Text] [Related]
7. Targeted literature review of the global burden of gastric cancer.
Casamayor M; Morlock R; Maeda H; Ajani J
Ecancermedicalscience; 2018; 12():883. PubMed ID: 30679950
[TBL] [Abstract][Full Text] [Related]
8. Comparing treatment and outcomes in advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas: a population-based study.
Pape M; Vissers PAJ; Dijksterhuis WPM; Bertwistle D; McDonald L; Mostert B; Derks S; Oving IM; Verhoeven RHA; van Laarhoven HWM
Ther Adv Med Oncol; 2023; 15():17588359231162576. PubMed ID: 36970109
[TBL] [Abstract][Full Text] [Related]
9. Best Practices for Managing Patients with Unresectable Metastatic Gastric and Gastroesophageal Junction Cancer in Canada.
Snow S; Gabrielson D; Lim H; Tehfe M; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(5):2552-2565. PubMed ID: 38785472
[TBL] [Abstract][Full Text] [Related]
10. TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study.
Raimondi A; Palermo F; Prisciandaro M; Aglietta M; Antonuzzo L; Aprile G; Berardi R; Cardellino GG; De Manzoni G; De Vita F; Di Maio M; Fornaro L; Frassineti GL; Granetto C; Iachetta F; Lonardi S; Murialdo R; Ongaro E; Pucci F; Ratti M; Silvestris N; Smiroldo V; Spallanzani A; Strippoli A; Tamberi S; Tamburini E; Zaniboni A; Di Bartolomeo M; Cremolini C; Sposito C; Mazzaferro V; Pietrantonio F
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34200267
[TBL] [Abstract][Full Text] [Related]
11. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.
Bang YJ; Kang YK; Ng M; Chung HC; Wainberg ZA; Gendreau S; Chan WY; Xu N; Maslyar D; Meng R; Chau I; Ajani JA
Eur J Cancer; 2019 Feb; 108():17-24. PubMed ID: 30592991
[TBL] [Abstract][Full Text] [Related]
12. Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Chung HC; Arkenau HT; Lee J; Rha SY; Oh DY; Wyrwicz L; Kang YK; Lee KW; Infante JR; Lee SS; Kemeny M; Keilholz U; Melichar B; Mita A; Plummer R; Smith D; Gelb AB; Xiong H; Hong J; Chand V; Safran H
J Immunother Cancer; 2019 Feb; 7(1):30. PubMed ID: 30717797
[TBL] [Abstract][Full Text] [Related]
13. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
14. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
[TBL] [Abstract][Full Text] [Related]
15. Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
Chau I; Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Sanchez T; Maglinte GA; Laurie M; Abraham P; Patel D; Shangguan T
Gastric Cancer; 2020 Jan; 23(1):133-141. PubMed ID: 31549264
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling.
Martin-Romano P; Solans BP; Cano D; Subtil JC; Chopitea A; Arbea L; Lozano MD; Castanon E; Baraibar I; Salas D; Hernandez-Lizoain JL; Trocóniz IF; Rodriguez J
PLoS One; 2019; 14(5):e0215970. PubMed ID: 31071108
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Alsina M; Moehler M; Hierro C; Guardeño R; Tabernero J
Target Oncol; 2016 Aug; 11(4):469-77. PubMed ID: 26880697
[TBL] [Abstract][Full Text] [Related]
18. Novel Systemic Therapies for Advanced Gastric Cancer.
Kim HJ; Oh SC
J Gastric Cancer; 2018 Mar; 18(1):1-19. PubMed ID: 29629216
[TBL] [Abstract][Full Text] [Related]
19. Research Progress of Immunotherapy for Gastric Cancer.
Zhang Z; Liu N; Sun M
Technol Cancer Res Treat; 2023; 22():15330338221150555. PubMed ID: 37042029
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
